망막 생물제제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Retinal Biologics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 7,161,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,458,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,179,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 세계 망막 생물제제 시장에 대한 종합적인 보고서를 발표하여 성장 촉진요인, 동향, 시장 성장 촉진요인, 과제 등 주요 시장 역학에 대한 상세한 분석을 제공했습니다. 이 상세한 보고서는 시장 구조와 예측 기간 동안의 성장 잠재력에 대한 통찰력을 제공합니다.

주요 인사이트

• 망막 생물제제 시장 규모(2024E) : 249억 달러
• 예상 시장 규모(2031F) : 429억 달러
• 세계 시장 성장률(CAGR 2024-2031) : 8.1%

망막 생물제제 시장 - 보고서 범위 :

망막 생물제제는 노화성 황반변성(AMD), 당뇨망막병증 등 지속성 망막질환을 치료하는 데 사용되는 생물공학 물질입니다. 이러한 생물제제는 미생물, 동물 세포, 식물 세포와 같은 생물체에서 유래하며, 일반적으로 안구 내 약물 전달 방식으로 투여됩니다. 노인 인구 증가와 함께 전 세계적으로 망막 질환의 유병률이 증가함에 따라 시장 성장을 주도하고 있습니다.

시장 성장의 촉진요인:

세계 망막 생물제제 시장의 성장을 이끄는 주요 요인으로는 AMD, 당뇨망막병증과 같은 망막 질환의 유병률 증가와 전 세계 노인 인구 증가가 주요 요인으로 꼽힙니다. 또한, 표적 치료를 위한 VEGF-A 길항제 및 TNF-a 억제제와 같은 생물제제의 채택이 증가함에 따라 시장 성장을 더욱 촉진하고 있습니다.

시장 성장 억제요인 :

성장 잠재력에도 불구하고, 망막 생물제제 시장은 높은 개발 및 제조 비용, 엄격한 규제 프로세스, 생물제제에 따른 부작용 등의 문제에 직면해 있습니다. 이러한 요인들은 접근성 제한과 망막 생물제제 치료의 가격 상승으로 인해 시장 성장을 저해할 수 있습니다.

시장 기회 :

망막 생물제제 시장은 안구 내 약물 전달 방법의 혁신과 무독성 및 환경 친화적인 생물제제 시장 개척으로 인해 큰 성장 기회를 제공합니다. 또한, 망막 치료에서 자가포식 조절의 도입은 새로운 치료법에 대한 유망한 전망을 제시합니다.

본 보고서에서 다룬 주요 질문들

• 세계 망막 생물제제 시장을 이끄는 주요 요인은?
• 망막 생물제제가 가장 많이 채택된 지역은 어디이며, 이러한 성장에 영향을 미치는 추세는 무엇인가?
• 안약 전달의 발전은 경쟁 구도에 어떤 영향을 미쳤는가?
• 망막 생물제제 시장의 주요 기업은 어디이며, 시장 지위를 유지하기 위해 어떤 전략을 취하고 있는가?
• 망막 생물제제 세계 시장에서의 새로운 트렌드와 미래 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
  • 세계의 의료비 지출 전망
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 있는 인사이트

• 규제 상황
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter의 Five Forces 분석

제4장 세계의 망막 생물제제 시장 전망 : 과거와 예측

• 주요 하이라이트
  • 시장 규모(10억 달러)와 전년대비 성장률
  • 절대적인$기회
• 시장 규모(10억 달러) 분석과 예측
  • 과거 시장 규모 분석, 2019년-2023년
  • 현재 시장 규모 분석과 예측, 2024-2031년
• 세계의 망막 생물제제 시장 전망 : 약제 클래스별
  • 서론/주요 조사 결과
  • 시장 규모 분석, 2019년-2023년
  • 시장 규모 분석과 예측, 2024년-2031년
    • VEGF-A 길항제
    • TNF-α 억제제
• 시장의 매력 분석 : 약제 클래스
• 세계의 망막 생물제제 시장 전망 : 적응증별
  • 서론/주요 조사 결과
  • 시장 규모 분석, 2019년-2023년
  • 시장 규모 분석과 예측, 2024년-2031년
    • 황반변성
    • 당뇨병성 황반부종
    • 당뇨병 망막증
    • 포도 막염
    • 기타
• 시장의 매력 분석 : 적응증
• 세계의 망막 생물제제 시장 전망 : 유통 채널별
  • 서론/주요 조사 결과
  • 시장 규모 분석, 2019년-2023년
  • 시장 규모 분석과 예측, 2024년-2031년
    • 기관투자가용 판매
    • 소매 약국
    • 통신 판매 약국
    • 소매 판매
• 시장의 매력 분석 : 유통 채널

제5장 세계의 망막 생물제제 시장 전망 : 지역별

• 주요 하이라이트
• 시장 규모 분석, 2019년-2023년
• 시장 규모 분석과 예측, 2024년-2031년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제6장 북미 망막 생물제제 시장 전망 : 과거(2019년-2023년) 및 예측(2024년-2031년)

제7장 유럽 망막 생물제제 시장 전망 : 과거(2019년-2023년) 및 예측(2024년-2031년)

제8장 동아시아 망막 생물제제 시장 전망 : 과거(2019년-2023년) 및 예측(2024년-2031년)

제9장 남아시아 및 오세아니아 망막 생물제제 시장 전망 : 과거(2019년-2023년) 및 예측(2024년-2031년)

제10장 라틴아메리카 망막 생물제제 시장 전망 : 과거(2019년-2023년)와 예측(2024년-2031년)

제11장 중동 및 아프리카 망막 생물제제 시장 전망 : 과거(2019-2023) 및 예측(2024-2031)

제12장 경쟁 구도

• 시장 점유율 분석, 2024년
• 시장 구조
  • 시장별 경쟁 강도 매핑
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Spark Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis Pharma AG
  • MeiraGTx Limited
  • Oxurion NV
  • Santen Pharmaceutical Co., Ltd.
  • Bayer AG
  • Bausch Health Companies Inc.
  • Merck & Co., Inc.
  • Adverum Biotechnologies

제13장 부록

• 조사 방법
• 조사 전제
• 두자어 및 약어

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Retinal Biologics Market, offering an in-depth analysis of key market dynamics, including growth drivers, trends, opportunities, and challenges. This detailed report provides insights into the market structure and growth potential over the forecast period.

Key Insights:

• Retinal Biologics Market Size (2024E): US$24.9 billion
• Projected Market Value (2031F): US$42.9 billion
• Global Market Growth Rate (CAGR 2024 to 2031): 8.1%

Retinal Biologics Market - Report Scope:

Retinal biologics are bioengineered substances used to treat persistent retinal disorders such as age-related macular degeneration (AMD) and diabetic retinopathy. These biologics are derived from living organisms, including microbes, animal cells, or plant cells, and are typically administered through ocular drug delivery methods. The increasing prevalence of retinal diseases worldwide, coupled with the growing elderly population, is driving the market's growth.

Market Growth Drivers:

Several key factors are driving the growth of the global Retinal Biologics Market. The rising prevalence of retinal disorders, such as AMD and diabetic retinopathy, and the growing elderly population worldwide are significant contributors. Moreover, the increasing adoption of biologics like VEGF-A antagonists and TNF-a inhibitors for targeted treatments is further propelling market growth.

Market Restraints:

Despite the growth potential, the Retinal Biologics Market faces challenges such as high development and manufacturing costs, stringent regulatory processes, and side effects associated with biologics. These factors can hinder market growth by limiting accessibility and increasing the price of retinal biologic treatments.

Market Opportunities:

The Retinal Biologics Market presents substantial growth opportunities through innovations in ocular drug delivery methods and the development of non-toxic, eco-friendly biologics. The introduction of autophagy modulation in retinal treatments also offers promising prospects for new therapies.

Key Questions Answered in the Report:

• What are the primary factors driving the global Retinal Biologics Market?
• Which regions are witnessing the highest adoption of retinal biologics, and what trends are influencing this growth?
• How are advancements in ocular drug delivery impacting the competitive landscape?
• Who are the leading players in the Retinal Biologics Market, and what strategies are they implementing to maintain their market positions?
• What are the emerging trends and future prospects in the global Retinal Biologics Market?

Competitive Intelligence and Business Strategy:

Leading players in the Retinal Biologics Market, such as Spark Therapeutics, F. Hoffmann-La Roche, and Regeneron Pharmaceuticals, are investing in research and development to introduce innovative biologic therapies. Collaborations with biotech firms and healthcare institutions are crucial for product development and market expansion. Addressing regulatory hurdles and ensuring the safety and efficacy of biologics will help companies maintain a competitive edge.

Key Companies Profiled:

• Spark Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• AbbVie Inc.
• Amgen Inc.
• Novartis Pharma AG
• MeiraGTx Limited
• Oxurion NV
• Santen Pharmaceutical Co., Ltd.
• Bayer AG
• Bausch Health Companies Inc.
• Merck & Co., Inc.
• Adverum Biotechnologies
• SemaThera Inc.

Retinal Biologics Market Segmentation:

By Product:

• VEGF-A Antagonists
• TNF-a Inhibitors

By Indication:

• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

By Distribution Channel:

• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

By Region:

• North America
• Europe
• Asia Pacific
• The Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Retinal Biologics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Value Chain Analysis
• 3.3. Key Deals and Mergers
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
• 4.3. Global Retinal Biologics Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 4.3.3.1. VEGF-A Antagonists
    • 4.3.3.2. TNF-a Inhibitors
• 4.4. Market Attractiveness Analysis: Drug Class
• 4.5. Global Retinal Biologics Market Outlook: Indication
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
    • 4.5.3.1. Macular Degeneration
    • 4.5.3.2. Diabetic Macular Edema
    • 4.5.3.3. Diabetic Retinopathy
    • 4.5.3.4. Uveitis
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Indication
• 4.7. Global Retinal Biologics Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Institutional Sales
    • 4.7.3.2. Retail Pharmacies
    • 4.7.3.3. Mail Order Pharmacies
    • 4.7.3.4. Retail Sales
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Retinal Biologics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Indication
  • 6.2.4. By Distribution Channel
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 6.4.1. VEGF-A Antagonists
  • 6.4.2. TNF-a Inhibitors
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 6.5.1. Macular Degeneration
  • 6.5.2. Diabetic Macular Edema
  • 6.5.3. Diabetic Retinopathy
  • 6.5.4. Uveitis
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.6.1. Institutional Sales
  • 6.6.2. Retail Pharmacies
  • 6.6.3. Mail Order Pharmacies
  • 6.6.4. Retail Sales
• 6.7. Market Attractiveness Analysis

7. Europe Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Indication
  • 7.2.4. By Distribution Channel
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 7.4.1. VEGF-A Antagonists
  • 7.4.2. TNF-a Inhibitors
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 7.5.1. Macular Degeneration
  • 7.5.2. Diabetic Macular Edema
  • 7.5.3. Diabetic Retinopathy
  • 7.5.4. Uveitis
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.6.1. Institutional Sales
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Mail Order Pharmacies
  • 7.6.4. Retail Sales
• 7.7. Market Attractiveness Analysis

8. East Asia Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Indication
  • 8.2.4. By Distribution Channel
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 8.4.1. VEGF-A Antagonists
  • 8.4.2. TNF-a Inhibitors
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 8.5.1. Macular Degeneration
  • 8.5.2. Diabetic Macular Edema
  • 8.5.3. Diabetic Retinopathy
  • 8.5.4. Uveitis
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.6.1. Institutional Sales
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Mail Order Pharmacies
  • 8.6.4. Retail Sales
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Indication
  • 9.2.4. By Distribution Channel
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 9.4.1. VEGF-A Antagonists
  • 9.4.2. TNF-a Inhibitors
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 9.5.1. Macular Degeneration
  • 9.5.2. Diabetic Macular Edema
  • 9.5.3. Diabetic Retinopathy
  • 9.5.4. Uveitis
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.6.1. Institutional Sales
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Mail Order Pharmacies
  • 9.6.4. Retail Sales
• 9.7. Market Attractiveness Analysis

10. Latin America Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Indication
  • 10.2.4. By Distribution Channel
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 10.4.1. VEGF-A Antagonists
  • 10.4.2. TNF-a Inhibitors
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 10.5.1. Macular Degeneration
  • 10.5.2. Diabetic Macular Edema
  • 10.5.3. Diabetic Retinopathy
  • 10.5.4. Uveitis
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.6.1. Institutional Sales
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Mail Order Pharmacies
  • 10.6.4. Retail Sales
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Indication
  • 11.2.4. By Distribution Channel
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 11.4.1. VEGF-A Antagonists
  • 11.4.2. TNF-a Inhibitors
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 11.5.1. Macular Degeneration
  • 11.5.2. Diabetic Macular Edema
  • 11.5.3. Diabetic Retinopathy
  • 11.5.4. Uveitis
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.6.1. Institutional Sales
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Mail Order Pharmacies
  • 11.6.4. Retail Sales
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Spark Therapeutics, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. F. Hoffmann-La Roche Ltd.
    • 12.3.2.1.Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Regeneron Pharmaceuticals, Inc.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. AbbVie Inc.
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Amgen Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Novartis Pharma AG
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. MeiraGTx Limited
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Oxurion NV
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Santen Pharmaceutical Co., Ltd.
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Bayer AG
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Bausch Health Companies Inc.
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Merck & Co., Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Adverum Biotechnologies
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료